BB Biotech: Setting the scene ahead of Q4/25 results - SEB

Following a prolonged period of valuation pressure, the biotech sector regained momentum through 2025 as monetary conditions became more supportive. BB Biotech benefited from this shift, with NAV up 26.5% in CHF YTD and the share price up 34.2% (CHF), clearly outperforming the Nasdaq Biotech Index, which rose 16.6%.

Länk till analysen i sin helhet: https://research.sebgroup.com/corporate/reports/138938